NEW YORK — Quest Diagnostics said Monday that it has secured a contract from the US Centers for Disease Control and Prevention to provide genomic sequencing of SARS-CoV-2.
Financial and other terms of the agreement were not disclosed.
The aim of the project is to identify novel mutations in the virus and to better understand its prevalence and patterns of transmission throughout the US.